Head and neck cancer in older adults: biological aging, treatment tolerance, and survivorship

Clicks: 10
ID: 334111
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #391 of 407 articles by views in JNCI Journal of the National Cancer Institute

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 407 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Head and neck squamous cell carcinoma (HNC) is increasingly diagnosed in older adults, a population characterized by substantial heterogeneity in physiologic reserve, comorbidity burden, functional status, and social support. Chronological age alone is an inadequate predictor of treatment tolerance and outcomes, yet it continues to influence therapeutic decision-making despite growing evidence supporting individualized assessment. This review summarizes the current evidence on aging and HNC, emphasizing the impact of comorbidities, frailty, comprehensive geriatric assessment (CGA), and biological aging on treatment selection, toxicity, and survival. We review validated geriatric assessment tools, including frailty measures and evaluation of cognitive, nutritional, and social domains, which consistently provide prognostic information beyond age and conventional performance status. Emerging data on immunologic aging and other biomarkers of biological aging suggest promising avenues for improving risk stratification, although these approaches remain investigational. We also discuss evidence from contemporary clinical trials, treatment adaptation and de-escalation strategies, implementation science, and the persistent underrepresentation of older adults in oncology research. Survivorship challenges, including late toxicities, functional decline, rehabilitation, and multidisciplinary long-term care, are reviewed alongside disparities in access to care that disproportionately affect older patients. Collectively, the available evidence supports a shift from age-based treatment decisions toward individualized care guided by physiologic reserve, geriatric assessment, and patient-centered goals. Future progress will depend on integrating geroscience, validated biomarkers of biological aging, geriatric-informed clinical trial design, and implementation strategies that improve equitable access to evidence-based care for the growing population of older adults with HNC.
Reference Key
openalex_W7223702318 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Maroun Bou Zerdan, Jad Assi, Youssef Bouferraa, Jana Abu Faraj, Nadeem Bilani, Brianna Brammer, Elias A Castro, Christophe Abi Zeid Daou, William A. Stokes, Soumon F. Rudra, James E. Bates, Anthea L. Hammond, Dong M Shin, Yong Teng, Nicole Cherie Schmitt, Nabil F. Saba
Are you one of these authors? Claim your profile
Journal JNCI Journal of the National Cancer Institute
Year 2026
DOI
10.1093/jnci/djag332
URL
https://doi.org/10.1093/jnci/djag332
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.